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Cardiomyocytes are the body’s ultimate endurance specialists. Recent advances provide insight into how cardio-
myocytes respond to injury and stress and reveal pathways that control cardiac growth in development and
disease. These findings point to new potential therapies for heart disease, including a surprising intervention
that wakes up dormant cardiomyocyte precursors after ischemic injury.The amount of nuclear-localized b -catenin (green) is greater
in Hippo-mutant cardiomyocytes (right) than in control cells
(left). Image courtesy of T. Heallen.Hippo Squashes Wnt Targets
InDrosophila, the Hippo-signaling pathway is awell-known orches-
trator of organismal size. Probing whether these mechanisms also
mould organogenesis in mammals, James Martin and colleagues
disrupted multiple Hippo pathway components in the developing
mouse heart. These targets for conditional knockout include the
MST kinases (the mammalian Hippo homologues), Salvador (a
scaffold protein that binds to MST kinases), and the kinase
LATS2 (a substrate of MST1/2). They show that disruption of this
pathway stimulates overgrowth of the heart due to an increase in
cardiomyocyte proliferation, which leads to additional malforma-
tions, including defects in the ventricular septum. Further analysis
showed that Wnt target genes are upregulated upon loss of the
Hippo pathway and that reducing levels of b-catenin (a core medi-
ator of Wnt signaling) suppressed cardiac overgrowth. Moreover,
the authors report a new element in the crosstalk between theHippo and Wnt pathways. When Hippo is inactive, the LATS2 substrate YAP is not phosphorylated and accumulates in
the nucleus, where it directly interacts with b-catenin. The resulting complex is recruited to growth-promoting genes,
including Sox2 and Snai2, activating their transcription. Future work may determine whether diminished signaling via this
pathway might contribute to the pathological reactivation of developmental programs in cardiac hypertrophy.
Heallen, T., et al. (2011). Science 332, 458–461.Phosphorylated SMAD (green) in
myocytes,fibroblasts,andsmooth
muscle cells. Image courtesy of
D. Kass.Under Pressure, TGF-b Becomes a Collaborator
Hypertension places heightened strain on the heart, which can ultimately lead to patholog-
ical changes such as hypertrophy and fibrosis. According to new work by David Kass and
colleagues, one factor contributing to these maladaptive responses is elevated signaling by
transforming growth factor b (TGFb). After inducing pressure overload in the mouse heart
using transverse aortic constriction, the authors observe a gradual increase in TGFb
signaling over the course of 9 weeks, which coincides with a progressive worsening of
cardiac hypertrophy and dysfunction. Remarkably, the pathological changes that occur
are suppressed by the cardiomyocyte-specific knockdown of the TGFb type 2 receptor
(but interestingly, not type 1 nor treatment with a neutralizing antibody directed at TGFb).
At the organ level, loss of the receptor preserved the density of capillaries in the myocar-
dium, consistent with the notion that maintenance or growth of the vasculature during
hypertrophy could be protective against the transition to heart failure. Delving further into
the molecular mechanisms of this effect, the authors provide evidence that the noncanon-
ical arm of the TGFb pathway (which is not dependent on SMAD proteins) is of particular
importance, specifically the regulation the kinase TAK1 and downstream expression of
bonemorphogentic protein 7 (BMP7). Whether TAK1 or BMP7might be targets for interven-
tion awaits exploration in future work.
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Masson stain of myocardial longitudinal
sections. Image courtesy of T. Mak.Cardiomyocytes Defended by a ROS Responder
Oxidative stress contributes to cardiac hypertrophy, and thus understanding how the
heart copes with its effects could lead to new therapeutic approaches for heart
disease. In a recent report, Tak Mak and colleagues implicate the mitochondrial
protein PTEN inducible kinase 1 (PINK1) in the protection of cardiomyocytes against
reactive oxygen species (ROS). In a mouse model, the authors show that PINK1 defi-
ciency promotes cardiac hypertrophy, increases the level of ROS, and enhances the
susceptibility of cardiomyocytes to ROS-induced cell death. At the cellular level,
PINK1 deficiency is shown to diminish the mitochondrial membrane potential in
a ROS-dependent manner. These phenotypes are not rescued by a kinase dead
version of PINK1, suggesting that identifying its relevant substrates in the heart will
provide further insight into disease mechanisms. The study also provides a connec-
tion to human disease, reporting that expression of PINK1 is decreased in patients
with end-stage heart failure. Although PINK1 is best known for its role in neuroprotec-tion given that recessive mutations in PINK1 cause early-onset Parkinson’s disease, this study raises the question of whether
human PINK1 mutations or polymorphisms might also contribute to cardiac phenotypes.
Billia, F., et al. (2011). Proc. Natl. Acad. Sci. USA 108, 9572–9577.A progenitor-derived cardiomyocyte
(red) bordering on a region of injured
myocardium (black areas). Image cour-
tesy of P. Riley.Endogenous Progenitors Nearing Prime Time
Prior work has reported that cardiomyocytes can arise from progenitor cells in the
outer layer of the heart known as the epicardium. Paul Riley and coworkers now
describe a means of reawakening this population of cells in adulthood in order to
promote the repair of damage caused by ischemic injury. Their approach involves
‘‘priming’’ this population of cells via the intraperitoneal injection of thymosin b4 prior
to the induction of a myocardial infarct. This treatment reactivates expression of
Wilm’s tumor 1 (Wt1), a marker of the epicardium in embryonic development that is
lost later in life. The cells that are induced can differentiate into cardiomyocytes and
thus serve as an endogenous source for repair. The authors had previously demon-
strated that this technique induces progenitors with the capacity to form new coro-
nary blood vessels. Thus, the current findings suggest that thymosin b4 may elicit
a broad spectrum of effects to reestablish an embryonic-like state in the adult heart.
Ascertaining how the effects of thymosin b4 are mediated may reveal additional
therapeutic targets to pursue or could provide clues for unlocking the regenerative
potential of other tissues damaged by injury or affected by age.
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